|
Name |
Nigragillin
|
| Molecular Formula | C13H22N2O | |
| IUPAC Name* |
(2E,4E)-1-[(2R,5S)-2,4,5-trimethylpiperazin-1-yl]hexa-2,4-dien-1-one
|
|
| SMILES |
C/C=C/C=C/C(=O)N1C[C@@H](N(C[C@H]1C)C)C
|
|
| InChI |
InChI=1S/C13H22N2O/c1-5-6-7-8-13(16)15-10-11(2)14(4)9-12(15)3/h5-8,11-12H,9-10H2,1-4H3/b6-5+,8-7+/t11-,12+/m0/s1
|
|
| InChIKey |
DVCNHRTYSUTLOS-OJRXFFSMSA-N
|
|
| Synonyms |
Nigragillin; Nigragilline; (2E,4E)-1-[(2R,5S)-2,4,5-trimethylpiperazin-1-yl]hexa-2,4-dien-1-one; 24779-38-2; MLS004256132; CHEBI:133753; DTXSID701141830; SMR003081017; N-Methyl-trans-2,5-dimethyl-N'-sorbylpiperazine; 1-[(2E,4E)-Hexa-2,4-dienoyl]-2,4,5-trimethylpiperazine; 1,2beta,5alpha-Trimethyl-4-[(2E,4E)-1-oxohexa-2,4-dienyl]piperazine; rel-(+)-(2E,4E)-1-[(2R,5S)-2,4,5-Trimethyl-1-piperazinyl]-2,4-hexadien-1-one
|
|
| CAS | 24779-38-2 | |
| PubChem CID | 15939563 | |
| ChEMBL ID | CHEMBL2208202 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 222.33 | ALogp: | 1.9 |
| HBD: | 0 | HBA: | 2 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 23.6 | Aromatic Rings: | 1 |
| Heavy Atoms: | 16 | QED Weighted: | 0.528 |
| Caco-2 Permeability: | -4.51 | MDCK Permeability: | 0.00003450 |
| Pgp-inhibitor: | 0.426 | Pgp-substrate: | 0.011 |
| Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.298 |
| 30% Bioavailability (F30%): | 0.495 |
| Blood-Brain-Barrier Penetration (BBB): | 0.638 | Plasma Protein Binding (PPB): | 55.17% |
| Volume Distribution (VD): | 1.136 | Fu: | 66.53% |
| CYP1A2-inhibitor: | 0.019 | CYP1A2-substrate: | 0.12 |
| CYP2C19-inhibitor: | 0.03 | CYP2C19-substrate: | 0.938 |
| CYP2C9-inhibitor: | 0.003 | CYP2C9-substrate: | 0.241 |
| CYP2D6-inhibitor: | 0.018 | CYP2D6-substrate: | 0.871 |
| CYP3A4-inhibitor: | 0.006 | CYP3A4-substrate: | 0.328 |
| Clearance (CL): | 5.352 | Half-life (T1/2): | 0.651 |
| hERG Blockers: | 0.108 | Human Hepatotoxicity (H-HT): | 0.919 |
| Drug-inuced Liver Injury (DILI): | 0.328 | AMES Toxicity: | 0.267 |
| Rat Oral Acute Toxicity: | 0.946 | Maximum Recommended Daily Dose: | 0.809 |
| Skin Sensitization: | 0.958 | Carcinogencity: | 0.846 |
| Eye Corrosion: | 0.162 | Eye Irritation: | 0.164 |
| Respiratory Toxicity: | 0.962 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001463 | ![]() |
0.321 | D00DKK | ![]() |
0.172 | ||
| ENC001733 | ![]() |
0.296 | D0G3PI | ![]() |
0.172 | ||
| ENC001748 | ![]() |
0.257 | D02DGU | ![]() |
0.172 | ||
| ENC002528 | ![]() |
0.257 | D0FG6M | ![]() |
0.165 | ||
| ENC002196 | ![]() |
0.250 | D03ZFG | ![]() |
0.160 | ||
| ENC005052 | ![]() |
0.247 | D0S2JI | ![]() |
0.159 | ||
| ENC004110 | ![]() |
0.243 | D06RCB | ![]() |
0.157 | ||
| ENC002015 | ![]() |
0.241 | D02IOH | ![]() |
0.157 | ||
| ENC003757 | ![]() |
0.240 | D0T3NY | ![]() |
0.151 | ||
| ENC001421 | ![]() |
0.240 | D0R0ZL | ![]() |
0.150 | ||